Evan Lippman
Executive Vice President of Business DevelopmentMr. Evan Lippman, MBA, is Executive Vice President of Business Development of Teva Pharmaceutical Industries Limited from March 31, 2025. Mr. Lippman served as Chief Corporate Development and Strategy Officer at Alnylam Pharmaceuticals, Inc. since September 2022 until March 2025. He served as Chief Financial Officer and Business Officer of Aileron Therapeutics, Inc. since January 2015 until December 31, 2016 and served as its Senior Vice President until December 31, 2016. Mr. Lippman served as Senior Vice President of Neurodegenerative Diseases and Rheumatology at EMD Serono, Inc. since June 14, 2012. He joined EMD Serono from AstraZeneca, where he served as Executive Director of the EMD Serono's multi-billion dollar Crestor(R) (rosuvastatin calcium) brand, following a number of leadership roles, including Executive Director and Head of US Business Development. Prior to AstraZeneca, he worked at Pfizer as Executive Director of Worldwide Business Development and Strategic Planning. He began his career in corporate finance and investment banking with such companies as Bank of America, Kurt Salmon Associates, Schroder & Co., Cohen & Steers Capital Advisors and the Bear Stearns Companies. Mr. Lippman holds a BA in Political Science from Bucknell University, a BA in Business from Georgia State University and an MBA from Cornell University.
Positions
- Company NameTeva Pharmaceutical Industries LimitedStock CodeTEVAPositionExecutive Vice President of Business DevelopmentColleagues
- RDRichard D. FrancisPresident, CEO & Director
- SJSol J. BarerIndependent Chairman of the Board
- ESEliyahu Sharon KalifExecutive VP & CFO
- CFChristine FoxExecutive VP of US Commercial & Head of Innovative Franchise
- MSMatthew ShieldsExecutive Vice President of Global Operations
- RARosemary A. CraneIndependent Director
- GMGerald M. LiebermanIndependent Director
- RARoberto Agostino MignoneIndependent Director
